Clinical Implications Of Aberrant TSG101 Transcripts In Acute Myeloblastic Leukemia

References

• Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–769
   PubMed Web of Science ®Google Scholar
• Bishop J. M. Cancer: the rise of the genetic paradigm. Genes Dev 1995; 9: 1309–1315
   PubMed Web of Science ®Google Scholar
• Ku W. H., Liu I. L., Yen M. S., Chang-Chien C. C., Yue C. T., Ma Y. Y., Chang S. F., Ng H. T., Wu C. W., Shen C. Y. Genomic deletion and p53 inactivation in cervical carcinoma. Int J Cancer 1997; 17: 270–276
   Web of Science ®Google Scholar
• Takita J., Hayashi Y., Yokota J. Loss of het-erozygosity in neuroblastomas - an overview. Eur J Cancer 1997; 33: 1971–1973
   PubMed Web of Science ®Google Scholar
• Drach J., Ackermann J., Fritz E., Kromer E., Schuster R., Gisslinger H., DeSantis M., Zojer N., Fiegel M., Roka S., Schuster J., Heinz R., Ludwig H., Huber H. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional - dose chemotherapy. Blood 1998; 92: 802–809
   PubMed Web of Science ®Google Scholar
• Li L., Cohen S. N. Tsg 101 : a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996; 85: 319–329
   PubMed Web of Science ®Google Scholar
• Li L., Li X., Francke U., Cohen S. N. The TSG101 tumor susceptibility gene is located in chromosome 11 band pl5 and is mutated in human breast cancer. Cell 1997; 88: 143–154
   PubMed Web of Science ®Google Scholar
• Lee M. P., Feinberg A. P. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 1997; 57: 3131–3134
   PubMed Web of Science ®Google Scholar
• Lin S. Y., Chen Y. J., Chang J. G. Multiple truncated transcripts of TSG101 in gastrointestinal cancers. J Gastroenterol Hepatol 1998; 13: 1111–1113
   PubMed Web of Science ®Google Scholar
• Maucuer A., Camonis J. H., Sobel A. Stathmin interaction with a putative kinase and coiled coil-forming protein domains. Proc Natl Acad Sci USA 1995; 92: 99–108
   Web of Science ®Google Scholar
• Koonin E. V., Abagyan R. A. TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet 1997; 16: 330–331
   PubMed Web of Science ®Google Scholar
• Ponting C. P., Cai Y. D., Bork P. J Mol Med 1997; 101: 467–469, The breast cancer gene product TSG: a regulator of ubiquitination?, 75
   Google Scholar
• Zhong Q., Chen C. F., Chen Y., Chen P. L., Lee W. H. Identification of cellular TSG101 protein in multiple human breast cancer cell lines. Cancer Res 1997; 57: 4225–4228
   PubMed Web of Science ®Google Scholar
• Xie W., Li L., Cohen S. N. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci USA 1998; 95: 1595–1600
   PubMed Web of Science ®Google Scholar
• Wagner K. U., Dierisseau P., Rucker E. B., Robinson G. W., Hennighausen L. Oncogene 1998; 101: 2761–2770, Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG: common types of shorter transcripts are true alternative splice variants., 17
   Web of Science ®Google Scholar
• Ferrer M., Lopez-Borges S., Lazo P. A. Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines. Oncogene 1999; 18: 2253–2259
   PubMed Web of Science ®Google Scholar
• Ali I. U., Lidereau R., Theillet C., Callahan R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 1987; 238: 185–188
   PubMed Web of Science ®Google Scholar
• Reeve A. E., Sih S. A., Raizis A. M., Feinberg A. P. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cel. Biot 1989; 9: 1799–1803
   PubMed Web of Science ®Google Scholar
• Steiner P., Barnes D. M., Harris W. H., Weinberg R. A. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat Gen 1997; 16: 332–333
   PubMed Web of Science ®Google Scholar
• Gayther S. A., Barski P., Batley S. J., Li L., de Foy K. A., Cohen S. N., Ponder B. A., Caldas C. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 1997; 15: 2119–2126
   PubMed Web of Science ®Google Scholar
• Sun Z., Pan J., Bubley G., Balk S. P. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene 1997; 15: 3121–3125
   PubMed Web of Science ®Google Scholar
• Lin P. M., Liu T. C., Chang J. G., Chen T. P., Lin S. F. Aberrant TSG101 transcripts in acute myeloid leukaemia. Br J Haematol 1998; 102: 753–758
   PubMed Web of Science ®Google Scholar
• Hampl M., Hampl J., Plachke J., Fitze G., Schackert G., Saeger H. D., Schackert H. K. Evidence that TSG101 aberrant transcripts are PCR artifacts. Bioche Bio-phys Res Commun 1998; 248: 753–760
   PubMed Web of Science ®Google Scholar
• Wang N. M., Chang J. G. Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related?. Int J Mol Med 1999; 3: 491–495
   PubMed Web of Science ®Google Scholar
• Wagner K. U., Dierisseau P., Rucker E. B., 3rd, Robinson G. W., Hennighausen; L. Oncogene 1998; 101: 2761–2770, Genomic architecture and transcriptional activation of the' mouse and human tumor susceptibility gene TSG: common types of shorter transcripts are true alternative splice variants., 17
   Web of Science ®Google Scholar